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We conducted a retrospective, nationwide multicenter study to evaluate the clini-
cal outcomes of proton beam therapy for bone sarcomas of the skull base and
spine in Japan. Eligibility criteria included: (i) histologically proven bone sarcomas
of the skull base or spine; (ii) no metastases; (iii) ≥20 years of age; and (iv) no prior
treatment with radiotherapy. Of the 103 patients treated between January 2004
and January 2012, we retrospectively analyzed data from 96 patients who were
followed-up for >6 months or had died within 6 months. Seventy-two patients
(75.0%) had chordoma, 20 patients (20.8%) had chondrosarcoma, and four patients
(7.2%) had osteosarcoma. The most frequent tumor locations included the skull
base in 68 patients (70.8%) and the sacral spine in 13 patients (13.5%). Patients
received a median total dose of 70.0 Gy (relative biological effectiveness). The
median follow-up was 52.6 (range, 6.3–131.9) months. The 5-year overall survival,
progression-free survival, and local control rates were 75.3%, 49.6%, and 71.1%,
respectively. Performance status was a significant factor for overall survival and
progression-free survival, whilst sex was a significant factor for local control.
Acute Grade 3 and late toxicities of ≥Grade 3 were observed in nine patients
(9.4%) each (late Grade 4 toxicities [n = 3 patients; 3.1%]). No treatment-related
deaths occurred. Proton beam therapy is safe and effective for the treatment of
bone sarcomas of the skull base and spine in Japan. However, larger prospective
studies with a longer follow-up are warranted.
B one sarcomas (BSs) are extremely rare, accounting for<0.2% of newly diagnosed malignant tumors in the United
States each year.(1) The primary definitive treatment for BSs is
surgical resection. However, BSs of the skull base (SB) and
spine are often difficult to resect completely. Radiotherapy is
an option for unresectable or partially resectable tumors,
although the majority of BSs are resistant to conventional pho-
ton radiotherapy. Therefore, photon radiotherapy has tradition-
ally been used in a neoadjuvant or adjuvant setting.(2, 3)
The efficacy of proton beam therapy (PBT) for BSs (primar-
ily chordomas and chondrosarcomas [CSs]) of the SB and
spine has been reported since the 1980s.(4–28) Photons emit
maximal energy near the body surface; this energy gradually
decreases at deeper points in the body. In contrast, charged
particles (e.g., protons and carbon ions) deposit a relatively
low-dose near the body surface and emit their maximum
energy just before they stop inside the body (the Bragg peak
effect). The Bragg peak effect may be spread out according to
the location and size of the tumor,(29,30) making it possible to
deliver high-dose radiation to the tumor, whilst limiting the
dose delivered to the organs at risk. The biological effects of
protons are almost identical to the biological effects of photons
(relative biological effectiveness [RBE], 1.1).(31)
Much evidence concerning the effectiveness of PBT for BSs of
the SB and spine has been reported from Western countries,
whereas only a limited number of small studies(7, 17, 22, 28) have
been published from Japan, even Asia. As of March 2012, six PBT
centers treated BSs in Japan since. These include the Hyogo Ion
Beam Medical Center, University of Tsukuba, Shizuoka Cancer
Center Hospital, National Cancer Center Hospital East, Southern
Tohoku General Hospital, and Fukui Prefectural Hospital.
We conducted a retrospective, nationwide multicenter study
to evaluate the clinical outcomes of PBT for BSs of the SB
and spine in Japan.
Materials and Methods
Study design and patients. We conducted a retrospective,
nationwide multicenter study across six PBT centers in Japan.
All patients provided written informed consent. The study
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protocol was approved by the appropriate Institutional Review
Board committee of each center. Research was conducted in
accordance with the Declaration of Helsinki (as revised in For-
taleza, Brazil, October 2013). Eligibility criteria included: (i)
histologically proven BSs of the SB or spine; (ii) no metastases;
(iii) ≥20 years of age; and (iv) no previous radiotherapy. Of the
103 patients treated between January 2004 and January 2012, we
retrospectively analyzed data from 96 patients (93.2%) who
were followed-up for >6 months or had died within 6 months.
The representative PBT planning procedure was as follows.
Radiation treatments were planned using a computed tomogra-
phy-based three-dimensional treatment planning system. Each
patient was immobilized using a custom-made thermoplastic
cast and computed tomography and magnetic resonance imag-
ing were performed. The target volumes and organs at risk were
delineated on computed tomography-magnetic resonance imag-
ing fusion images. The clinical target volume was defined as the
gross tumor volume plus a 5.0-mm basic margin, and the adja-
cent structures were included in selected patients. The planning
target volume was defined as the clinical target volume plus a
setup margin and an internal margin where necessary.
The reported dose of PBT was calculated by multiplying the
physical dose by the RBE of the protons (1.1). Since various
dose fractionations were adopted, the antitumor effects of PBT
were compared on the basis of a biologically effective dose,
alpha/beta ratio of 10.0 Gy (BED10). It is important to note that
although the alpha/beta ratios for BSs may be <10.0 Gy, the pre-
cise alpha/beta ratios for chordomas, CSs, and osteosarcomas
have yet to be determined. Therefore, we adopted an alpha/beta
ratio of 10.0 Gy that has been commonly used for antitumor
effects. BED10 was calculated as follows:
BED10 Gy RBE½ ð Þ ¼total dose Gy RBE½ ð Þ
f1þ dose per fraction
Gy RBE½ ð Þ=10 Gy RBE½ ð Þg
The following are examples of dose constraints in a 32-frac-
tion protocol: brainstem, optic nerve, and spinal cord (cauda
equina not included), maximum dose of ≤48.0 Gy (RBE);
small intestine, maximum dose of ≤52.0 Gy (RBE); large
intestine, maximum dose of ≤57.0 Gy (RBE); and rectum, vol-
ume receiving ≥65.0 Gy (RBE) of ≤17.0% and volume receiv-
ing ≥40.0 Gy (RBE) of ≤35.0%.
Representative treatment plans for PBT in patients with BSs
of the SB and spine are represented in Fig. 1.
Toxicities were evaluated using the Common Terminology
Criteria for Adverse Events, version 4.0.
Statistical analyses. Continuous variables are presented as
medians and ranges and categorical variables are presented as
frequencies and percentages. Overall survival (OS), progres-
sion-free survival (PFS), and local control (LC) curves were
estimated using the Kaplan–Meier method and compared by
the log-rank test. Variables with a P < 0.05 from the univari-
ate analysis were included in the multivariate analysis, using a
Cox proportional hazards model. All statistical analyses were
conducted using Statistical Package for the Social Sciences for
Windows, software version 23 (IBM Corp., Armonk, NY,
USA). A two-sided P < 0.05 was considered statistically sig-
nificant.
Results
Patients. Patient characteristics are summarized in Table 1.
Seventy-two patients (75.0%) had chordoma, 20 patients
(20.8%) had CS, and four patients (4.2%) had osteosarcoma.
The most frequent tumor location was the SB in 68 patients
(70.8%), followed by the sacral spine in 13 patients (13.6%).
Therefore, the most frequent combinations of histological sub-
types and tumor locations were chordoma of the SB (n = 53
patients; 55.2%), CS of the SB (n = 15 patients; 15.6%), and
chordoma of the sacrum (n = 12 patients; 2.5%). Pre-PBT, 68
patients (70.8%) underwent surgical resection. Fifty-five
(80.9%) of 68 patients with a tumor of the SB and 11 (73.3%)
of 15 patients with a tumor of the spine underwent surgical
resection, whereas only two (15.4%) of 13 patients with a tumor
of the sacrum underwent surgical resection. Four patients
(4.2%; osteosarcoma [n = 2 patients], CS [n = 1 patient], and
chordoma [n = 1 patient]) received chemotherapy pre-PBT.
Patients received a median total dose of 70.0 Gy (RBE)
(BED10, 86.0 Gy [RBE]). Three patients (3.1%) were treated
with combined PBT and photon radiotherapy (12.5–44.0 Gy in
5–22 fractions). Accelerated hyperfractionation (60.5–77.4 Gy
[RBE] in 50–64 fractions, twice daily) was administered to 20
patients (20.8%).
Survival and local control. The median follow-up was 52.6
(range, 6.3–131.9) months. The 5-year OS, PFS, and LC rates
for all 96 patients were 75.3% (95.0% confidence interval
[CI]: 65.7%–84.9%), 49.6% (95.0% CI: 38.6%–60.6%), and
71.1% (95.0% CI: 60.1%–82.1%), respectively (Fig. 2–3). The
5-year OS, PFS, and LC rates for chordoma patients (n = 72)
were 75.5% (95.0% CI: 63.9%–87.1%), 45.6% (95.0% CI:
32.7%–58.5%), and 68.4% (95.0% CI: 55.1%–81.7%), respec-
tively. The 5-year OS, PFS, and LC rates for CS patients
(n = 20) were 83.5% (95.0% CI: 66.3%–100.0%), 72.2%
(a) (b)
Fig. 1. Representative treatment plans for proton
beam therapy in (a) a 45-year-old female with skull
base chordoma (65.0 Gy [relative biological
effectiveness] delivered in 26 fractions) and (b) a
53-year-old female with sacral chordoma (70.4 Gy
[relative biological effectiveness] delivered in 32
fractions).
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(95.0% CI: 51.2%–93.2%), and 82.2% (95.0% CI: 63.8%–
100.0%), respectively. The 5-year OS, PFS, and LC rates for
patients with tumors of the SB (n = 68) were 77.6% (95.0%
CI: 66.6%–88.6%), 57.0% (95.0% CI: 44.3%–69.7%), and
76.2% (95.0% CI: 64.4%–88.0%), respectively. The 5-year
OS, PFS, and LC rates for patients with tumors of the spine
(n = 28) were 70.7% (95.0% CI: 51.7%–89.7%), 30.7%
(95.0% CI: 11.1%–50.3%), and 55.6% (95.0% CI: 30.3%–
80.9%), respectively. The 5-year OS, PFS, and LC rates for
patients with chordoma of the SB (n = 53) were 74.6%
(95.0% CI: 61.3%–87.9%), 52.8% (95.0% CI: 38.1%–67.5%),
and 73.8% (95.0% CI: 59.9%–87.7%), respectively.
During follow-up, 27 (28.1%) and 19 patients (19.8%) expe-
rienced local (in-field) or regional/distant (out-of-field) recur-
rences, respectively. Frequent sites of out-of-field recurrence
included regional (n = 8 patients; 8.3%) and bone metastases
(n = 4 patients; 4.2%).
A performance status (PS) of 0–1 was associated with a sig-
nificantly longer OS (log-rank test, P < 0.001; Table 2). PS
(0–1; P < 0.001), tumor location (SB; P = 0.019), and plan-
ning target volume (≤70.0 mL; P = 0.026) were associated
Table 1. Patient characteristics
Characteristic Patients (n = 96)
Age, years
Median (range) 56 (20–80)
<60 55 (57.3)
≥60 41 (42.7)
Sex, n (%)
M 51 (53.1)
F 45 (46.9)
PS, n (%)
0 39 (40.6)
1 50 (52.1)
2 5 (5.2)
3 2 (2.1)
Histological subtype, n (%)
CH 72 (75.0)
CS 20 (20.8)
OSA 4 (4.2)
Tumor location, n (%)
SB 68 (70.8)
Cervical spine 8 (8.3)
Lumbar spine 5 (5.2)
Lumbosacral spine 2 (2.1)
Sacral spine 13 (13.6)
Tumor status, n (%)
Primary 73 (76.0)
Recurrent 23 (24.0)
Surgery, n (%)
Pre-PBT 68 (70.8)
Post-PBT 2 (2.1)
None 26 (27.1)
Chemotherapy, n (%)
Pre-PBT 4 (4.2)
Post-PBT 0 (0.0)
None 92 (95.8)
PTV, mL
Median (range) 72 (9–1,984)
≤70 48 (50.0)
>70 48 (50.0)
Radiotherapy, n (%)
PBT alone 93 (96.9)
PBT + photon radiotherapy 3 (3.1)
Total dose, Gy (RBE)†
Median (range) 70 (50–84)
≤70 50 (52.1)
>70 46 (47.9)
BED10, Gy (RBE)†
Median (range) 86 (60–103)
≤85 49 (51.0)
>85 47 (49.0)
†The sums of the photon dose/BED10 and proton dose/BED10 were
used for patients treated with PBT + photon radiotherapy. BED10, bio-
logically effective dose, alpha/beta = 10 Gy; CH, chordoma; CS, chon-
drosarcoma; F, female; M, male; OSA, osteosarcoma; PBT, proton
beam therapy; PS, performance status; PTV, planning target volume;
RBE, relative biological effectiveness; SB, skull base.
Fig. 2. Kaplan–Meier curve of overall survival (OS) for all 96 patients
with bone sarcoma of the skull base and spine.
Fig. 3. Kaplan–Meier curves of local control (LC) and progression-
free survival (PFS) for all 96 patients with bone sarcoma of the skull
base and spine.
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with a significantly longer PFS, while female sex was associ-
ated with a significantly improved LC rate (P = 0.041). Histo-
logical subtype, surgery, and BED10 were not associated with
OS, PFS, or LC.
The Cox proportional hazards model revealed that only a PS
of 0–1 was associated with a significantly longer PFS
(P < 0.001), whilst tumor location (SB) exhibited a trend
towards a longer PFS (P = 0.053; Table 3).
Toxicities. Grade 3 acute toxicities occurred in nine patients
(9.4%). The most frequent toxicity was dermatitis in four
patients (4.2%). All patients completed the planned radiother-
apy and subsequently recovered from their reactions. No acute
toxicities of ≥Grade 4 occurred.
Late toxicities of ≥Grade 3 occurred in nine patients (9.4%).
Grade 3 late toxicities included musculoskeletal and connec-
tive tissue disorders in three patients (3.1%; deformity [n = 2]
and necrosis [n = 1]), eye disorders in one patient (1.0%;
blurred vision and pain), middle ear inflammation in one
patient (1.0%), and pain in one patient (1.0%). Grade 4 late
toxicities included tissue necrosis in two patients (2.1%) and a
brainstem infarction in one patient (1.0%). The patient suffer-
ing from a brainstem infarction received a high-dose (maxi-
mum, 65.3 Gy [RBE] with a mean of 46.7 Gy [RBE]) to the
brainstem. No treatment-related deaths occurred.
Discussion
Our study is the first to evaluate PBT for BSs of the SB and
spine on a nationwide multicenter basis in Japan. To the best
of our knowledge, this study comprises the largest cohort of
patients among reports published from Asia. Our findings are
promising given that BSs of the SB and spine are difficult to
resect completely. Recently, reports regarding particle therapy,
including PBT and carbon ion radiotherapy,(32–36) for BSs of
the SB and/or spine have been increasing rapidly, especially
between 2014 and 2016. The results of recent studies, from
2011 to 2016, are summarized in Table 4. With respect to his-
tological subtype, CS patients were generally associated with
more favorable outcomes compared to chordoma patients.
Weber et al.(25) demonstrated in a multivariate analysis that
CS patients had a significantly improved OS and LC rate com-
pared to chordoma patients. In our study, histological subtype
was not a significant factor for OS, PFS, or LC. Regarding the
comparison between PBT and carbon ion radiotherapy, there
appears to be no apparent differences between these two treat-
ment modalities. Mima et al.(22) published the results of parti-
cle therapy using carbon ions or protons as a definitive
treatment for primary sacral chordoma patients and reported
that there were no significant differences between the two ion
types. Although a randomized controlled trial is needed to val-
idate this finding, a German group is conducting a phase II
trial of PBT and carbon ion radiotherapy for chordomas of the
SB, CSs of the SB, and sacrococcygeal chordomas.(37–39)
In the present study, univariate and multivariate analyses
revealed that a PS of 0–1 was associated with a significantly
longer OS (P < 0.001) and PFS (P < 0.001), whereas female
sex was associated with a significantly improved LC rate
(P = 0.041). To the best of our knowledge, this is the first
report to identify PS as a significant prognostic factor,
although most previously published reports did not include PS
as a variable in the prognostic analyses. The statistical signifi-
cance of PS may be due to chance alone since it was highly
unbalanced between the two groups (0–1: n = 89 vs. 2–3:
n = 7). However, it is logical that PS would affect survival.
Table 2. Log-rank test results
Variable
Patients
(n = 96)
P-value
OS PFS LC
Age, years
<60 55
≥60 41 0.167 0.455 0.380
Sex
M 51
F 45 0.606 0.455 0.041*
PS
0–1 89
2–3 7 <0.001* <0.001* 0.066
Histological subtype
CH 72
Other 24 0.773 0.194 0.169
Tumor location
SB 68
Spine 28 0.524 0.019* 0.176
Tumor status
Primary 73
Recurrent 23 0.393 0.077 0.067
Surgery
Pre-PBT 68
Post-PBT/none 28 0.241 0.537 0.971
Chemotherapy
Pre-PBT 4
Post-PBT/none 92 0.065 0.117 0.880
PTV, mL
≤70 48
>70 48 0.056 0.026* 0.154
Radiotherapy
PBT alone 93
PBT + photon
radiotherapy
3 0.280 0.145 0.193
BED10, Gy (RBE)
≤85 49
>85 47 0.250 0.240 0.637
*P < 0.05. BED10, biologically effective dose, alpha/beta = 10 Gy; CH,
chordoma; F, female; LC, local control; M, male; OS, overall survival;
PBT, proton beam therapy; PFS, progression-free survival; PS, perfor-
mance status; PTV, planning target volume; RBE, relative biological
effectiveness; SB, skull base.
Table 3. Cox proportional hazards model results
Covariate Patients (n = 96)
PFS
95% CI P-value
PS
0–1 89
2–3 7 0.071–0.441 <0.001*
Tumor location
SB 68
Spine 28 0.992–3.283 0.053
PTV, mL
≤70 48
>70 48 0.890–2.859 0.116
*P < 0.05. CI, confidence interval; PFS, progression-free survival; PS,
performance status; PTV, planning target volume; SB, skull base.
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Staab et al.(18) and Mima et al.(22) reported that male chor-
doma patients had a significantly longer OS and PFS than
female chordoma patients. Conversely, in the present study
comprising 72 chordoma patients (75.0%), female sex was
associated with a significantly improved LC rate. Several
hypotheses have been proposed to explain the possible influ-
ence of sex on the treatment outcome of chordoma patients, as
reviewed by Halperin.(40) For instance, sex hormone receptors
may represent an influential factor in adult chordoma patients
and genetic factors may also play a role in determining clinical
outcomes. Although not statistically significant overall, a plan-
ning target volume of ≤70.0 mL was associated with a signifi-
cantly longer PFS in the univariate analysis (P = 0.026), but
not the multivariate analysis (P = 0.116), and exhibited a trend
towards a longer OS (P = 0.056). Several other stud-
ies(11,15,18,25,41) have demonstrated that tumor volume is a sig-
nificant prognostic factor.
Proton beam therapy-related acute and late toxicities
appeared to be tolerable. Grade 3 acute toxicities were
reversible and did not influence treatment schedules. Nine
patients (9.4%) experienced ≥Grade 3 late toxicities with a
median follow-up of 52.6 months. However, the tumors were
close to the affected organs and the events were considered
to be unavoidable in all cases. Grade 4 brainstem infarction
occurred in a patient with CS of the SB. Information con-
cerning radiation-associated toxicities is very limited in the
literature, most probably because most published series are
retrospective studies that extend back several decades to
accumulate an adequate number of patients. In such a sce-
nario, two long-term studies of PBT for BSs of the SB or
spine(20, 25) have been published. DeLaney et al.(20) reported
Grade 3/4 late toxicities in 10.0% and 13.0% of spinal chor-
doma, CS, and other sarcoma patients at 5 and 8 years,
respectively, whereas Weber et al.(25) reported Grade 3/4 late
toxicities in 8.1% of SB chordoma and CS patients with a
median follow-up of 50.0 months. Our results are compara-
ble with the findings of these two studies. Despite high
doses to treatment volumes, accompanying toxicities were
relatively low, even though the majority of tumors were
located in regions adjacent to the organs at risk (i.e., the
brainstem, optic nerve, and spinal cord), because the precise
dose distribution of PBT could limit doses to critical struc-
tures.
This study has three important limitations. The foremost are
its retrospective design and the relatively low impact of the
statistical analyses. However, many previously published stud-
ies have also used a retrospective design, which is likely
related to the difficulty of performing a prospective study
given the rarity of the disease. Second, the follow-up period
was relatively short (median, 52.6 months) and the major his-
tological subtypes (chordoma and CS) in this study are slow
growing with the potential for recurrence 5 years post-PBT.
Therefore, we will continue to monitor these patients with the
intention of being able to report on follow-up data. Finally, PS
was highly unbalanced between the two groups (0–1: n = 89
vs. 2–3: n = 7), and thus, the statistical significance of this
variable may have occurred by chance alone. However, we
identified no biased estimates with unstable standard errors in
our multivariate analysis.
In conclusion, we are the first to demonstrate the safety and
efficacy of PBT for BSs of the SB and spine in a retrospective,
nationwide multicenter study in Japan. Larger prospective
studies with a longer follow-up are required to validate these
findings.
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Table 4. Recent studies of particle therapy for bone sarcomas of the skull base and/or spine
Author(s) Year Patients Histological subtype Tumor location Therapy OS LC
Staab et al.(18) 2011 40 CH Spine P  X  S 80% (5y) 62% (5y)
Fuji et al. (17) 2011 16 CH/CS SB P  S 100% 100% (CH),
86% (CS) (3y)
Matsumoto et al. (32) 2013 47 CH/CS/OSA/Other Spine C  S 52% (5y) 79% (5y)
Uhl et al. (33) 2014 155 CH SB C  S 85% (5y) 72% (5y)
Uhl et al. (34) 2014 79 CS SB C  S 96% (5y) 88% (5y)
DeLaney et al. (20) 2014 50 CH/CS/Other Spine X + P  S 84% (5y) 81% (5y)
Deraniyagala et al. (21) 2014 33 CH SB P  S 92% (2y) 86% (2y)
Mima et al. (22) 2014 23 CH Sacrum C or P 83% (3y) 94% (3y)
Rotondo et al. (23) 2015 126 CH Spine X + P  S 81% (5y) 62% (5y)
Uhl et al. (35) 2015 56 CH Sacrum C  IMRT 52% (5y) 79% (5y)
Holliday et al. (24) 2015 19 CH/CS Spine S + P 93% (2y) 58% (2y)
Weber et al. (25) 2016 222 CH/CS SB S + P 86% (5y) 81% (5y)
Imai et al. (36) 2016 188 CH Sacrum C 81% (5y) 77% (5y)
Feuvret et al. (26) 2016 159 CS SB S + P 96% (5y) 95% (5y)
Indelicato et al. (27) 2016 51 CH/CS Spine P  S 72% (4y) 58% (4y)
Hayashi et al. (28) 2016 19 CH SB S + P 83% (5y) 75% (5y)
Current study 2016 96 CH/CS/OSA SB, Spine P  S 75% (5y) 71% (5y)
C, carbon ion; CH, chordoma; CS, chondrosarcoma; IMRT, intensity modulated radiotherapy; LC, local control; OS, overall survival; OSA, osteosar-
coma; P, proton; S, surgery; SB, skull base; X, photon; y, year.
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Abbreviations
BED10 biologically effective dose, alpha/beta ratio of 10.0 Gy
BS bone sarcoma
CI confidence interval
CS chondrosarcoma
LC local control
OS overall survival
PBT proton beam therapy
PFS progression-free survival
PS performance status
RBE relative biological effectiveness
SB skull base
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